Date: Oct. 8th, 2022 Your Name: Jimmy Bar

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa:	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

	all discussed to the		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
5	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
В	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_X_None	

None.	

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th, 2022 Your Name: Xi Zhi

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa:	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Support for attending	_X_None	
Rill	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		THE RESIDENCE OF THE PARTY OF T
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of stock options	xNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		

None.		71-2	WAR FAIR	

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th, 2022

Your Name: Has-Yu Yuan

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	THE RESERVE OF THE PERSON NAMED IN COLUMN 1	Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_None	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_X_None	
3	Patents planned, issued or pending	XNone	
,	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
1	Stock or stock options	XNone	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
.3	Other financial or non- financial interests	XNone	

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th, 2022 Your Name: Jan - Xi Chen

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

	Re Walning & State St		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_None	
	Payment for expert testimony	XNone	
	Support for attending meetings and/or travel	XNone	
	Patents planned, issued or pending	XNone	
	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
1	Stock or stock options	_X_None	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
3	Other financial or non- financial interests	XNone	

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th,	2022		C1
Your Name:	101:n8-	Kum	(INDN

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_None	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	X_None	

None.	Plotter All In	1.000	

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th, 2022 Your Name: Jun-Haw Zhon

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	建设是各种数据的地址的	Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	State Swelling and State

	Alterial Society	53 33 39 4 6 9 9	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
5	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
	Patents planned, issued or pending	XNone	
	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
1	Stock or stock options	XNone	
	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
3	Other financial or non- financial interests	XNone	

None.		
	- 필요대한다는 시트웨티트 (12 - 12) 스웨이티드 [17]	

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th, 2022

Your Name: Kang-Yi Xue

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	_X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

None.			100

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th, 2022 Tran-Kun Yang

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
100		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	X None	

	A THE RESIDENCE OF THE PARTY.		THE SECOND SECON
		HOMAS MALE STATES	
5	Payment or honoraria for lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	ST PUBLISHED HELD AND A SUPERIOR ARTHURST AND A SUPERIOR OF THE PARTY
	testimony		
7	Support for attending	V N	Late British that a reference the province of the control of
1	meetings and/or travel	_X_None	
	and a survey		
A S			
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or Advisory Board	Contract Contract	
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy	Ally days and	
	group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical	^_None	
	writing, gifts or other	HI WANTER ADDR	A SERVICE CONTRACTOR OF THE SERVICE AND A SE
	services		
13	Other financial or non-	XNone	The state of the s
	financial interests		
	A STATE OF THE PARTY OF THE PAR		

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct. 8th, 2022 Your Name: Twn - Dong Liv

Manuscript Title: Overexpression of SPHK1 associated with targeted therapy resistance predicts poor prognosis in renal

cell carcinoma

Manuscript number (if known): TCR-22-417

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initi	al planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone					
		Time frame: pas	st 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone					
3	Royalties or licenses	XNone					
4	Consulting fees	X_None					

		100000000000000000000000000000000000000	And the second second
-		V 11-2	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None	
5	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_X_None	
	Patents planned, issued or pending	XNone	
	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
1	Stock or stock options	XNone	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
3	Other financial or non- financial interests	_X_None	

None.					

Please place an "X" next to the following statement to indicate your agreement: